Literature DB >> 7680113

A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices.

P Sriramarao1, M A Bourdon.   

Abstract

Sequence analysis of two human tenascin encoding cDNA clones from a cDNA library of the U251 glioblastoma cell line revealed the presence of a novel 276 bp tenascin type III fibronectin like repeat. This alternatively spliced type III repeat designated AD1 is located between the previously identified repeats 10 and 11 and has sequence homology with human, chicken and mouse tenascin type III repeats. These results show that tenascin has at least 16 consecutive fibronectin like type III repeats. PCR amplification of random primed mRNA with specific type III repeat primers revealed a pattern of multiple alternative splices of AD1 and flanking type III repeats. The alternative splice variants were confirmed by direct sequencing. Differences were observed in the expression of the various alternative splices of tenascin mRNA between tumor and normal cells and may thus indicate differences in tenascin isoform expression and function in normal and tumor cells. PCR and Southern analysis of genomic DNA indicate that AD1 is coded by a single exon present in both human and mouse genome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680113      PMCID: PMC309079          DOI: 10.1093/nar/21.1.163

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  39 in total

1.  Identification of two distinct regions of the type III connecting segment of human plasma fibronectin that promote cell type-specific adhesion.

Authors:  M J Humphries; A Komoriya; S K Akiyama; K Olden; K M Yamada
Journal:  J Biol Chem       Date:  1987-05-15       Impact factor: 5.157

2.  A HindIII polymorphism in the 3' end of the human alpha 1(IV) collagen gene.

Authors:  L Tikka; K Roiko; R Soininen; D J Prockop; K Tryggvason
Journal:  Nucleic Acids Res       Date:  1987-07-10       Impact factor: 16.971

3.  Three different fibronectin mRNAs arise by alternative splicing within the coding region.

Authors:  J E Schwarzbauer; J W Tamkun; I R Lemischka; R O Hynes
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

Review 4.  Molecular biology of fibronectin.

Authors:  R Hynes
Journal:  Annu Rev Cell Biol       Date:  1985

5.  Identification of an alternatively spliced site in human plasma fibronectin that mediates cell type-specific adhesion.

Authors:  M J Humphries; S K Akiyama; A Komoriya; K Olden; K M Yamada
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

6.  Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein.

Authors:  M A Bourdon; T J Matthews; S V Pizzo; D D Bigner
Journal:  J Cell Biochem       Date:  1985       Impact factor: 4.429

Review 7.  Alternative splicing of fibronectin: three variants, three functions.

Authors:  J E Schwarzbauer
Journal:  Bioessays       Date:  1991-10       Impact factor: 4.345

8.  Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.

Authors:  M A Bourdon; C J Wikstrand; H Furthmayr; T J Matthews; D D Bigner
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

9.  Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene.

Authors:  A R Kornblihtt; K Umezawa; K Vibe-Pedersen; F E Baralle
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

10.  Tenascin promotes cerebellar granule cell migration and neurite outgrowth by different domains in the fibronectin type III repeats.

Authors:  K Husmann; A Faissner; M Schachner
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

View more
  12 in total

1.  Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes.

Authors:  D Fischer; R P Tucker; R Chiquet-Ehrismann; J C Adams
Journal:  Mol Biol Cell       Date:  1997-10       Impact factor: 4.138

2.  Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2.

Authors:  Kelly Foley; Stephen Muth; Elizabeth Jaffee; Lei Zheng
Journal:  Cell Adh Migr       Date:  2017-02-06       Impact factor: 3.405

3.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

4.  Tenascin-C and human tendon degeneration.

Authors:  G P Riley; R L Harrall; T E Cawston; B L Hazleman; E J Mackie
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

5.  Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

Authors:  B Carnemolla; P Castellani; M Ponassi; L Borsi; S Urbini; G Nicolo; A Dorcaratto; G Viale; G Winter; D Neri; L Zardi
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

6.  Melanoma Cell Invasive and Metastatic Potential Correlates with Endothelial Cell Reorganization and Tenascin Expression.

Authors:  P Sriramarao; Mario A Bourdon
Journal:  Endothelium       Date:  1996

7.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

Review 8.  Tenascins, a growing family of extracellular matrix proteins.

Authors:  R Chiquet-Ehrismann
Journal:  Experientia       Date:  1995-09-29

9.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

10.  Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours.

Authors:  K E Wilson; S P Langdon; A M Lessells; W R Miller
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.